ReviewWorld journal of nephrology2026
Endocrine disorders linked to chronic kidney disease: Mechanisms and clinical implications.
Review in World journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of kidney transplantation on sex hormone level and sexual function in end stage renal disease men.Frontiers in transplantation · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a progressive condition that disrupts multiple endocrine axes, contributing to a broad range of hormonal imbalances, including mineral and bone disorder, gonadal dysfunction, thyroid abnormalities, insulin resistance, and elevated prolactin levels. These disturbances not only exacerbate comorbidities such as cardiovascular disease, anemia, diabetes, and sarcopenia, but may also accelerate the decline of renal function. This article aims to provide a comprehensive overview of the pathophysiology, clinical impact, and management strategies for endocrine disorders in CKD. A narrative literature search was conducted using PubMed, EMBASE, the Cochrane Library, and Scielo through July 2025, focusing on 141 studies addressing endocrine complications in CKD. The prevalence of hormonal dysfunction increases with CKD progression, affecting over 70% of patients in advanced stages. Disruptions in calcium and phosphate homeostasis lead to secondary hyperparathyroidism, vascular calcification, and bone fragility. Thyroid hormone alterations and testosterone deficiency contribute to reduced muscle mass, fatigue, and cardiovascular risk. Impaired glucose metabolism complicates glycemic control, particularly in dialysis and post-transplant populations. Diagnostic interpretation is often challenged by altered hormone clearance and protein binding. Therapeutic approaches require individualized strategies, including dietary and pharmacological correction of mineral imbalances, cautious hormone replacement, and use of agents such as dopamine agonists or sodium-glucose cotransporter-2 inhibitors. A multidisciplinary approach integrating nephrology and endocrinology is essential to improve outcomes and quality of life in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.